Eikon Therapeutics annual shares outstanding
2023
2024
2025
Eikon Therapeutics Shares Outstanding History (EIKN)
Eikon Therapeutics reported 54.0M shares outstanding at the end of fiscal 2025.
View full Eikon Therapeutics company overviewEikon Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 54.0M | 0 | 0.00% |
| 2024 | 2024-12-31 | 54.0M | 0 | 0.00% |
| 2023 | 2023-12-31 | 54.0M | — | — |
Eikon Therapeutics quarterly shares outstanding
Q4.24
Q3.25
Q4.25
As of Mar 31, 2026
As of Jun 30, 2026
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| As of Jun 30, 2026 | 2026-06-30 | 54.1M | — | — |
| As of Mar 31, 2026 | 2026-03-31 | 54.1M | — | — |
| Q4 2025 | 2025-12-31 | 54.0M | 0 | 0.00% |
| Q3 2025 | 2025-09-30 | 54.0M | — | — |
| Q4 2024 | 2024-12-31 | 54.0M | — | — |
Eikon Therapeutics shares outstanding trends
Between the periods ended 2023-12-31 and 2025-12-31, Eikon Therapeutics's shares outstanding moved from 54.0M to 54.0M, a change of 0. The latest reported quarter, As of Jun 30, 2026, shows 54.1M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eikon Therapeutics source filings ↗